Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 350 participants.

Also called NCT07227246

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 350 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07227246
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Germany, Japan, Spain, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07227246. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-06 (actual); primary completion 2029-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
Acronym
FASTEST Part 2
Condition
Intracerebral Hemorrhage
Intervention (Biological)
Recombinant Factor VIIa
Intervention (Biological)
Biological/Vaccine: Placebo
Lead sponsor
Joseph Broderick, MD (class: other)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS) (class: US National Institutes of Health)
Collaborator
Japan Agency for Medical Research and Development (class: other government)
Collaborator
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07227246
Content hash
30d9be44ef3ab76437c7d79d4ada510e41427035c24fd16e5d65bf60e159e334